---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Long-term morbidity"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Long-term morbidity. Topics: Myasthenic crisis: frequency, triggers, and outcomes; Myasthenic crisis: Ontario, Canada, population-based incidence; Exacerbations and crises: predictors and inpatient use, United States generalized myasthenia gravis; Hospitalization trends: United States, 2010 to 2019; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Myasthenic crisis: frequency, triggers, and outcomes

> “Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.”
> “MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.”
> “Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.”
> “MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.”
> “The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.”

Source: [Claytor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114503/)

> “A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks”
> “Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-2"></a>

### Myasthenic crisis: Ontario, Canada, population-based incidence

> “Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.7-3"></a>

### Exacerbations and crises: predictors and inpatient use, United States generalized myasthenia gravis

> “Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).”
> “After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index.”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-4"></a>

### Hospitalization trends: United States, 2010 to 2019

> “Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001).”
> “The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.7-5"></a>

### Refractory disease: persistent moderate or severe weakness

> “However, 10%–20% of patients continue to have long‐standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.7-6"></a>

### Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001”
> “Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).”
> “Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)”
> “Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.”
> “Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.7-7"></a>

### Glucocorticoid toxicity: recognized adverse effects and higher-risk patients

> “However, long-term use of GCs is associated with potentially serious toxicities, including weight gain, cataracts, hypertension, diabetes, osteoporosis, infections, and neuropsychiatric symptoms”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

> “MG patients with osteoporosis, obesity, diabetes, and mental disorders have a particularly high risk of corticosteroid side effects.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
